Abstract 1676 Characterization of Cdc14 Phosphatase inhibitors as potential antifungal lead compounds

The occurrence of invasive fungal disease has been increasing in recent years, claiming approximately 3.8 million lives annually, with immuno-compromised individuals at the highest risk of contracting these deadly infections. Only three classes of antifungal drugs (azoles, echinocandins, and polyenes) are currently approved for treating invasive fungal infections, leaving patients with limited options for adequate treatment. Thus, there is a great need to develop new drugs to combat fungal disease.